Premium
Pharmacokinetics of Daily Self‐Application of Imiquimod 3.75% Cream in Adult Patients With External Anogenital Warts
Author(s) -
Wu Jason,
Feldman Robert,
Barry Gabrielle T.,
Kulp James,
Adams Michael P.,
Levy Sharon
Publication year - 2012
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270011407192
Subject(s) - imiquimod , medicine , dosing , pharmacokinetics , adverse effect , dermatology
Imiquimod 3.75% cream is a new formulation intended for daily self‐application. The objective of this study was to characterize serum imiquimod pharmacokinetics under maximal use conditions. Adults with ≥8 warts or total wart area ≥100 mm 2 applied up to 1 packet of imiquimod 3.75% cream (250 mg cream, 9.375 mg imiquimod) once daily for 3 weeks. Blood was obtained prior to doses 1, 7, 14, and 21 and at selected time points after doses 1 and 21. Eighteen patients (13 men and 5 women) with a median wart count of 16 and total wart area of 60 mm 2 were enrolled. Day 21 mean (SD) serum C max was 0.49 (0.37) ng/mL, AUC 0–24 6.80 (3.59) ng·h/mL, and t 1/2 24.1 (12.4) hours. Steady state was achieved by day 7 with ∼2‐fold increase in C max and AUC after multiple dosing. Overall, C max was higher and t max shorter in women, with comparable AUC 0–24 . Imiquimod metabolites were sporadically quantifiable. No patients discontinued for adverse events; 1 interrupted dosing for an application site ulcer. Treatment‐related adverse events occurred in 16.7% of the patients. In conclusion, serum imiquimod concentrations were low after daily self‐application to external anogenital warts of up to 1 packet of imiquimod 3.75% cream for 21 days.